European equities traded in the US as American depositary receipts were higher late Tuesday morning, rising 0.59% to 1,393.03 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by Spanish lender Banco Santander (SAN) and biotech company Evaxion Biotech (EVAX), which rose 3.8% and 2.5% respectively. They were followed by software firm SAP (SAP) and Spanish financial services company Banco Bilbao Vizcaya Argentaria (BBVA), which were up 2% and 1.9% respectively.
The decliners from continental Europe were led by semiconductor company Sequans Communications (SQNS) and accommodations booking company trivago (TRVG), which dropped 9.6% and 8.5% respectively. They were followed by biopharmaceutical companies Cellectis (CLLS) and argenx (ARGX), which were down 2.5% and 2% respectively.
From the UK and Ireland, the gainers were led by oil and gas company Shell (SHEL) and British bank Barclays (BCS), which increased 1.7% and 1.5% respectively. They were followed by medical device maker Smith & Nephew (SNN) and British financial services company HSBC (HSBC), which were up 1.4% and 1.1% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and pharmaceutical company Silence Therapeutics (SLN), which fell 16% and 11% respectively. They were followed by biopharmaceutical companies Akari Therapeutics (AKTX) and Bicycle Therapeutics (BCYC), which lost 7.4% and 3.5% respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.